Crizotinib-d 8

Overview

Crizotinib-d 8 (PF-02341066-d 8 ) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC 50 s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC 50 s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition.

Application

Products | Products > Signaling Pathways > Others | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Isotope-Labeled Compounds | Products > Signaling Pathways > c-Met/HGFR | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > ROS Kinase | Products > Signaling Pathways > Anaplastic lymphoma kinase (ALK)

Product Information

• Catalog No.: HY-50878S1
• CAS No.: 1523579-82-9
• Molecular Formula: C21H14D8Cl2FN5O
• Molecular Weight: 458.39
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source